BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38184304)

  • 1. VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial.
    Coffman-D'Annibale K; Myojin Y; Monge C; Xie C; Hrones DM; Wood BJ; Levy EB; Kleiner D; Figg WD; Steinberg SM; Redd B; Greten TF
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38184304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer.
    Akce M; Farran B; Switchenko JM; Rupji M; Kang S; Khalil L; Ruggieri-Joyce A; Olson B; Shaib WL; Wu C; Alese OB; Diab M; Lesinski GB; El-Rayes BF
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy: A Phase 1 Nonrandomized Clinical Trial.
    Fakih M; Sandhu J; Lim D; Li X; Li S; Wang C
    JAMA Oncol; 2023 May; 9(5):627-634. PubMed ID: 36892833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Johnson B; Haymaker CL; Parra ER; Soto LMS; Wang X; Thomas JV; Dasari A; Morris VK; Raghav K; Vilar E; Kee BK; Eng C; Parseghian CM; Wolff RA; Lee Y; Lorenzini D; Laberiano-Fernandez C; Verma A; Lang W; Wistuba II; Futreal A; Kopetz S; Overman MJ
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 36007963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer.
    Wang C; Chevalier D; Saluja J; Sandhu J; Lau C; Fakih M
    Oncologist; 2020 Aug; 25(8):e1188-e1194. PubMed ID: 32406541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of the tumor-selective adenovirus enadenotucirev, in combination with nivolumab, in patients with advanced/metastatic epithelial cancer: a phase I clinical trial (SPICE).
    Fakih M; Harb W; Mahadevan D; Babiker H; Berlin J; Lillie T; Krige D; Carter J; Cox C; Patel M; Parfitt L; Powell M; Rosen L
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37094988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXD101 and nivolumab in patients with metastatic microsatellite-stable colorectal cancer (CAROSELL): a multicentre, open-label, single-arm, phase II trial.
    Saunders MP; Graham J; Cunningham D; Plummer R; Church D; Kerr R; Cook S; Zheng S; La Thangue N; Kerr D
    ESMO Open; 2022 Dec; 7(6):100594. PubMed ID: 36327756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.
    Lemech C; Dredge K; Bampton D; Hammond E; Clouston A; Waterhouse NJ; Stanley AC; Leveque-El Mouttie L; Chojnowski GM; Haydon A; Pavlakis N; Burge M; Brown MP; Goldstein D
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination Treatment of Intratumoral Vidutolimod, Radiosurgery, Nivolumab, and Ipilimumab for Microsatellite Stable Colorectal Carcinoma With Liver Metastases.
    Margalit O; Lieberman S; Redinsky I; Halparin S; Honig N; Raskin S; Ben-Ayun M; Shacham-Shmueli E; Halpern N; Urban D; Ackerstein A; Shulman K; Ben-Ami E; Semenisty V; Purim O; Yarom N; Golan T; Boursi B; Appel S; Symon Z; Berger R; Mauro D; Krieg AM; Lawrence YR
    Clin Colorectal Cancer; 2023 Dec; 22(4):442-449.e1. PubMed ID: 37657954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
    Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704).
    Kawazoe A; Itahashi K; Yamamoto N; Kotani D; Kuboki Y; Taniguchi H; Harano K; Naito Y; Suzuki M; Fukutani M; Higuchi T; Ikeno T; Wakabayashi M; Sato A; Koyama S; Nishikawa H; Shitara K
    Clin Cancer Res; 2021 Dec; 27(24):6709-6715. PubMed ID: 34593531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.
    Kim RD; Chung V; Alese OB; El-Rayes BF; Li D; Al-Toubah TE; Schell MJ; Zhou JM; Mahipal A; Kim BH; Kim DW
    JAMA Oncol; 2020 Jun; 6(6):888-894. PubMed ID: 32352498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial.
    Cousin S; Cantarel C; Guegan JP; Gomez-Roca C; Metges JP; Adenis A; Pernot S; Bellera C; Kind M; Auzanneau C; Le Loarer F; Soubeyran I; Bessede A; Italiano A
    Clin Cancer Res; 2021 Apr; 27(8):2139-2147. PubMed ID: 33495314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O
    Morano F; Raimondi A; Pagani F; Lonardi S; Salvatore L; Cremolini C; Murgioni S; Randon G; Palermo F; Antonuzzo L; Pella N; Racca P; Prisciandaro M; Niger M; Corti F; Bergamo F; Zaniboni A; Ratti M; Palazzo M; Cagnazzo C; Calegari MA; Marmorino F; Capone I; Conca E; Busico A; Brich S; Tamborini E; Perrone F; Di Maio M; Milione M; Di Bartolomeo M; de Braud F; Pietrantonio F
    J Clin Oncol; 2022 May; 40(14):1562-1573. PubMed ID: 35258987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).
    Cloughesy TF; Brenner A; de Groot JF; Butowski NA; Zach L; Campian JL; Ellingson BM; Freedman LS; Cohen YC; Lowenton-Spier N; Rachmilewitz Minei T; Fain Shmueli S; ; Wen PY
    Neuro Oncol; 2020 May; 22(5):705-717. PubMed ID: 31844890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.
    Lenz HJ; Van Cutsem E; Luisa Limon M; Wong KYM; Hendlisz A; Aglietta M; García-Alfonso P; Neyns B; Luppi G; Cardin DB; Dragovich T; Shah U; Abdullaev S; Gricar J; Ledeine JM; Overman MJ; Lonardi S
    J Clin Oncol; 2022 Jan; 40(2):161-170. PubMed ID: 34637336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.